Eli Lilly
Pays vs peer median
×1.09
+9% premium
Sample
26
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.16 | 20 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.22 | 7 |
| phase 3 | ×1.01 | 5 |
| phase 2 | ×1.07 | 4 |
| discovery | ×0.70 | 4 |
| preclinical | ×1.50 | 4 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Morphomer Tau | AC Immune SA | Alzheimer's disease and other neurodegenerative diseases | preclinical | $10M | $1.7B |
| 2026 | AI-developed oral therapeutics (multiple preclinical programs) | Insilico Medicine | multiple | preclinical | $115M | $2.8B |
| 2026 | ophthalmic gene therapies | Adverum Biotechnologies | AMD/Diabetic retinopathy | unknown | — | $262M |
| 2026 | oral obesity treatments | Nimbus Therapeutics | obesity | discovery | — | $1.3B |
| 2026 | STAC-BBB AAV capsid | Sangamo Therapeutics | CNS diseases | discovery | $18M | $1.4B |
| 2026 | neurological gene-editing therapies | Verve Therapeutics | neurological diseases | preclinical | $1.3B | $1.3B |
| 2026 | in vivo CAR-T program | Orna Therapeutics | autoimmune diseases | unknown | $2.4B | $2.4B |
| 2026 | DECODE platform | Repertoire Immune Medicines | autoimmune | discovery | $85M | $1.9B |
| 2026 | Anti-KIT-001 | ORIC Pharmaceuticals | NSCLC | discovery | $62M | $619M |
| 2025 | PARP-301 | Syndax Pharmaceuticals | CLL | phase_2 | $320M | $2.9B |
| 2025 | Nectin-4-001 | Xencor | Prostate | phase_3 | $659M | $5.3B |
| 2025 | Anti-SIRPα-301 | Karyopharm Therapeutics | Head & Neck | approved | $1.4B | $5.5B |
| 2025 | mTOR-tinib | Roivant Sciences | AML | preclinical | $26M | $406M |
| 2025 | long-acting GLP-1/incretin technology | Camurus | — | unknown | — | $870M |
| 2025 | CLDN18.2-301 | CytomX Therapeutics | Mantle Cell Lymphoma | phase_2 | $269M | $2.2B |
How this is computed
For each Eli Lilly deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 26 disclosed deal premiums vs. peer medians. Raw premium 1.090, clamped to [0.7, 1.5].